Epilepsy Therapeutics Market Strategy Analysis And Trends To 2019
In 2012, the overall industry for epilepsy therapeutics in the major developed markets contributed for an approximate share of over $3.1 billion. Furthermore, this market is anticipated to expand at a total CAGR of over 3.3% to cross over $4.2 billion over the forecast period till 2019.
In 2012, the overall industry for epilepsy therapeutics in the major developed markets contributed for an approximate share of over $3.1 billion. Furthermore, this market is anticipated to expand at a total CAGR of over 3.3% to cross over $4.2 billion over the forecast period till 2019.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
1.1 List of Tables 7<br />
1.2 List of Figures 8<br />
2 Introduction 9<br />
2.1 Disease Overview 9<br />
2.2 Epidemiology 9<br />
2.3 Symptoms 11<br />
2.4 Etiology 11<br />
2.5 Pathophysiology 12<br />
2.6 Co-morbidities/Complications 12<br />
2.7 Diagnosis 12<br />
2.8 Prognosis 13<br />
2.9 Treatment Efficacy 13<br />
2.10 Treatment Options 14<br />
2.10.1 Ion Channel Modulators 14<br />
2.10.2 GABA-ergic Facilitation 15<br />
2.10.3 Excitatory Amino Acid Inhibitors 15<br />
2.10.4 Synaptic Modulators 15<br />
2.11 Non-pharmacological Management 15<br />
2.11.1 Lobectomy and Lesionectomy 15<br />
2.11.2 Ketogenic Diet and Modified Atkins Diet 15<br />
2.11.3 Vagus Nerve Stimulation 16<br />
Browse All Reports of This Category @<br />
http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare<br />
3 <strong>Epilepsy</strong> Therapeutic Landscape 17<br />
3.1 Overview 17<br />
3.2 Lyrica (pregabalin) 17<br />
3.3 Lamictal (lamotrigine) 18<br />
3.4 Keppra (levetiracetam) 19<br />
3.5 Zonegran (zonisamide) 21<br />
3.6 Vimpat (lacosamide) 22<br />
3.7 Aptiom/Zebinix (eslicarbazepine acetate) 24<br />
3.8 Fycompa (perampanel) 24<br />
3.9 Trobalt/Potiga (ezogabine/retigabine) 25<br />
3.10 Banzel/Inovelon (rufinamide) 26<br />
3.11 Comparative Efficacy and Safety of <strong>Market</strong>ed Products 26<br />
4 Pipeline for <strong>Epilepsy</strong> <strong>Therapeutics</strong> 29<br />
4.1 Overall Pipeline 29<br />
4.2 Pipeline by Mechanism of Action 31<br />
4.3 Clinical Trials 32<br />
4.3.1 Failure Rate 32<br />
4.3.2 Patient Enrolment and Clinical Trial Size 34
Change language